Prot #D4190C00021: A Phase 1b/2 Study of MEDI4736 in Combination with Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects with Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Project: Research project

StatusFinished
Effective start/end date6/16/166/16/19

Funding

  • PRA Health Sciences (Prot #D4190C00021)
  • MedImmune, LLC (Prot #D4190C00021)